R&D Issues Around HIV/AIDS
March 18, 2011
In the final post in a four-part series examining research and development issues around HIV, the Center for Global Health Policy's "Science Speaks" features a Q&A with Michael Johnson, deputy director of the Fogarty International Center at the National Institutes of Health (NIH), who discusses the aims of the Medical Education Partnership Initiative (MEPI), a $130 million program funded by PEPFAR and NIH, to bolster the health workforce and researchers in developing countries. As Johnson explains, "core funding for MEPI comes from PEPFAR, so a focus of the programs is HIV/AIDS. But there is also NIH funding to the projects, and this expands the program past HIV/AIDS into issues such as training in child and maternal health, cancer, heart disease, mental health, and emergency medicine" (Donnelly, 3/11). A second post features a Q&A with Kevin DeCock, director of the Center for Global Health at the CDC, who describes the ongoing studies of microbicides and the need to coordinate resources to maximize resources in this area (Donnelly, 3/10).
This article was provided by Henry J. Kaiser Family Foundation. It is a part of the publication Kaiser Daily Global Health Policy Report. Visit the Kaiser Family Foundation's website to find out more about their activities, publications and services.
Add Your Comment:
(Please note: Your name and comment will be public, and may even show up in
Internet search results. Be careful when providing personal information! Before
adding your comment, please read TheBody.com's Comment Policy.)